|Bid||3.36 x 1400|
|Ask||5.00 x 900|
|Day's Range||3.2600 - 3.5600|
|52 Week Range||1.5000 - 6.2900|
|Beta (3Y Monthly)||4.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.50|
NEW YORK, Jan. 07, 2019 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,.
The direct benefit for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
Checkpoint Therapeutics, Inc. (CKPT) delivered earnings and revenue surprises of -45.45% and -98.08%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you want to know who really controls Checkpoint Therapeutics Inc (NASDAQ:CKPT), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk Read More...
CK-101 is the company’s most advanced candidate intended for non-small cell lung cancer (NSCLC) and addresses some of the shortcomings of previous generation drugs. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is an orally administered therapy under development for lung cancer patients whose tumors carry EGFR mutations, including the T790M resistance mutation. Preliminary results of the trial were accepted as a late-breaking submission.
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) announced today that it will present results from the CK-101 Phase I/II program at the World Conference on Lung Cancer on Monday, September 24 in Toronto, ...
Checkpoint Therapeutics, Inc. (CKPT) delivered earnings and revenue surprises of 34.29% and -65.68%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.
It was only eight years ago, at the June 2010 American Society of Clinical Oncology conference, when Bristol Myers presented groundbreaking data showing a significant survival advantage in melanoma for ipilimumab, the first successful checkpoint blockade inhibitor (CBI). This announcement followed years of failures in the immuno-oncology space with highly touted compounds such as Sanofi’s iniparib, GSK’s Elesclomol and many others falling by the wayside.
Although overlooked by the investors, Checkpoint Therapeutics (CKPT) looks well positioned for a solid gain evident from its favorable Zacks rank and positive estimate revision.
Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ...